Currently, the combination of PD-1/PD-L1 inhibitors and small molecule inhibitors has been reported in many literatures and clinical trials, which can bring great benefits to different kinds of cancer patients, including nivolumab, pembrolizumab, PDR001, TSR-042, avelumab, atezolizumab, etc. Although no specific combination of PD-1/PD-L1 immune checkpoint inhibitors and small molecule inhibitors has been reported in GC, we still can learn the relevant details of drug combination in different malignant diseases in other studies (98). The gene discussed is CD274; the disease is cancer.